Structure-free AI platform delivers picomolar leads while cutting wet-lab validation to 20-50 samples per round
Ainnocence Inc., an AI-driven pharmaceutical & material IP-generatingplatform company, today reported performance results from 75 completed proteindesign programs and announced that it is seeking licensing and partneringagreements for 28 antibody, bispecific and ADC programs that have generatedpositive preclinical data across oncology, immunology and metabolicindications.
Across 58affinity maturation campaigns, Ainnocence's SentinusAI® platform succeeded in 53, a 91.4%program success rate, with only five campaigns failing to produce an improvedbinder. On novel targets attempted with no structural information and no priorbinder, 9 of 17 de novo campaigns (53%) yielded validated hits.
Performancewithout structure
Unlike 3Dstructure-dependent approaches, SentinusAI® predicts binding directly fromsequence, removing the requirement for a resolved co-crystal or predictedcomplex. That design choice underpins both the platform's throughput and itseconomics: Ainnocence reports a roughly 10,000-fold reduction in computationalcost relative to conventional 3D modeling workflows, a computation cycle of oneto two weeks per round, and capacity to run more than 100 programsconcurrently.
The practicaleffect is on the wet lab. Because each round is narrowed to 20-50 designs beforesynthesis, partners test tens of molecules rather than thousands:
· De novo design: 7.5% positive rate on round-1zero-shot prediction, rising to 30% on round-2 reinforcement-learning iteration
· Affinitymaturation: 21.5%positive rate on round-1 zero-shot prediction, rising to 43.8% on round-2iteration
· Affinity gainsfrom tens- to thousands-fold over the parent molecule, with leads reachingpicomolar potency
Picomolarleads across formats
Deliveredprograms span Fabs, scFvs, mAbs, bispecifics and ADC-enabling binders.Of the campaigns with quantified KD readouts, 28 reached sub-nanomolaraffinity and seven reached 100 pM or better. Leading results include anIL-15×IL-21 bispecific at approximately 0.09 pM on the IL-21 arm, a TNFα-OX40Lbispecific at 8.6 pM, an anti-C1q program at 1-20 pM and a TL1A×p40 bispecificat 23 pM. An anti-VEGF scFv-IgG measured 27.8-34.6 pM by SPR, outperforming thebevacizumab reference run in the same experiment.
Twenty-eightprograms available for licensing
Ainnocence'sinternal pipeline comprises 37 programs, of which 28 have produced positivedata and are now available for licensing or partnering, individually or as aportfolio. Highlights include a TL1A×p40 bispecific (KD 0.16 nM; benchmarkduvakitug, Phase 3), an anti-IL-36R Fab with 13 of 21 matured variants bindingbelow the 1 pM detection limit (benchmark spesolimab-class HB-0034), ananti-TROP2 ADC lead at 0.37-0.43 nM with confirmed internalization (benchmarkTrodelvy) and an anti-B7-H3 program at approximately 0.56 nM (benchmarkifinatamab deruxtecan, Phase 2). Seven ADC-ready internalizing oncology targetshave been validated by FACS, and internalization assay and leads have expressedat titers up to approximately 440 mg/L at greater than 99% SEC purity.
“Thenumber that matters to a partner is not how many molecules our model can score,it is how many they have to make,”said Dr.Lurong Pan, PhD, Founder and CEO of Ainnocence. “Twenty to fiftydesigns per round, one to two weeks of compute and a 91.4% program success rateacross 58 maturation campaigns is a different operating model for antibodydiscovery. And because we never depended on a resolved structure, the targetsother platforms set aside are the ones we take on.”
Collaboratewith Ainnocence
Ainnocence isseeking licensing and partnering relationships to advance the pipeline throughaffinity finalization, ADC conjugation, in vivo efficacy and clinicaldevelopment. Additional non-confidential and confidential materials areavailable on request.
About AinnocenceInc.
Founded in2021 and headquartered in California, Ainnocence is a next-generationbiotechnology company transforming drug discovery and synthetic biology throughAI-based, sequence-first engineering. Ainnocence’s self-evolving platformevaluates up to 10 billion molecules spanning proteins, antibodies, smallmolecules, nucleic acids, and chemical formulations within hours to weeks,enabling rapid, multi-objective design across therapeutic, biological, andchemical systems. By reducing R&D timelines and costs while increasingsuccess rates, Ainnocence empowers industry and academic partners to pursuecomplex biological innovation with greater precision and control.
Contact:
Dr. Lurong Pan,PhD
+1205-249-7424